CTX-IKaulu veselībaLaboratorijas rezultātu interpretācija
CTX can show how actively bone is being broken down, but the result is highly sensitive to sampling conditions, treatment and kidney function.
Medicīniski pārskatījis Tomass Kleins, MD
Galvenie secinājumi
- CTX meaning: CTX-I is a blood marker of collagen breakdown and reflects bone resorption, not bone mineral density or fracture risk by itself.
- Gavēšana: Food can suppress CTX, so many laboratories request an overnight fast of 8-12 hours before a morning sample.
- Diennakts laiks: CTX commonly peaks overnight and falls during the day; a morning result is not directly comparable with an afternoon result.
- Vienības: CTX may appear as pg/mL or ng/L; these two units are numerically equivalent, while 1 ng/mL equals 1,000 pg/mL.
- Medikamentu ietekme: Bisphosphonates and denosumab usually lower CTX, whereas teriparatide and abaloparatide can raise it during bone-building treatment.
- Diagnosis limit: A single CTX value cannot diagnose osteoporosis; diagnosis relies mainly on DXA bone mineral density, fracture history and clinical risk.
- Nieru funkcija: Reduced kidney clearance can raise CTX independently of increased bone resorption, making renal results part of interpretation.
- Atkārtota pārbaude: Repeat CTX under the same fasting, morning and laboratory conditions when monitoring a treatment response.
What does the CTX blood test measure?
The CTX bone turnover marker measures bone resorption, the process in which osteoclasts break down old bone and release fragments of type I collagen into the circulation. CTX does not measure bone density directly, and a result outside a laboratory interval does not prove osteoporosis or bone loss.

Serum CTX-I, also called the C-terminal telopeptide test, detects a fragment released when type I collagen is degraded. About 90% of the organic matrix of bone is type I collagen, so CTX acts as a short-term biochemical signal of osteoclast activity rather than a direct scan of skeletal strength.
A CTX result can change within hours, while a DXA scan reflects accumulated mineral density over months or years. For example, a hypothetical 62-year-old with CTX of 720 pg/mL may have active resorption, but that number alone cannot tell us whether the person has osteoporosis, a recent fracture, menopause-related turnover or a medication effect.
Kantesti is an AI blood test analyzer that places CTX beside related results such as calcium, phosphate, alkaline phosphatase, creatinine and vitamin D rather than treating the marker as a diagnosis. Our Par mums lapā explains how we distinguish an interpretation aid from clinical diagnosis.
Why one CTX result cannot diagnose osteoporosis
One CTX value cannot diagnose osteoporosis because CTX reflects current resorption, whereas osteoporosis is diagnosed from bone mineral density, fragility fractures and overall fracture risk. A high result may indicate increased turnover, but it does not quantify how much bone has been lost.

The diagnostic threshold for osteoporosis is a DXA T-score of −2.5 or lower at the femoral neck, total hip or lumbar spine in appropriate postmenopausal women and men aged 50 years or older. CTX has no equivalent universal diagnostic cutoff, because assay calibration, age, sex, menopause and kidney function alter the result.
A low CTX can also be misleading. A person taking alendronate may have CTX below 100 pg/mL with stable treatment, while another person with the same value may have naturally low turnover; the number does not distinguish those situations without medication history and prior results.
CTX can complement fracture-risk assessment but should not replace it. The asins analīžu biomarķieru ceļvedis provides broader context for reading a biomarker pattern, including why a result that is statistically unusual is not automatically clinically dangerous.
Does fasting change CTX test results?
Fasting usually makes CTX easier to compare because food suppresses circulating CTX, particularly after carbohydrate-containing meals. Many laboratories therefore request an overnight fast of 8-12 hours and a morning collection, although the exact instruction belongs to the ordering laboratory.

A meal can lower CTX through insulin and nutrient-related changes in bone metabolism, with suppression lasting several hours. The size of the effect varies; a practical interpretation is that a non-fasting CTX of 180 pg/mL may not be comparable with a fasting result of 420 pg/mL drawn from the same person on another day.
Water is generally permitted during a fasting blood test, while calories, milk, sweetened drinks and many nutritional supplements may break the fast. Do not stop prescribed medicines unless the clinician or laboratory specifically instructs you; the purpose is to standardise the sample, not to create medication risk.
Frāze CTX fasting test is not a separate assay. It means the same serum CTX measurement collected under fasting conditions; preparation details can be checked in our guide to what fasting required means.
Why does the time of day matter for CTX?
CTX follows a circadian rhythm: concentrations are generally higher overnight and in the early morning, then decline during the day. A 7:30 a.m. fasting sample and a 3:00 p.m. non-fasting sample should not be used as if they were interchangeable.

In many adults, CTX is lowest in the afternoon and rises during sleep, with peak-to-trough differences often around 20-50%. The precise pattern varies by age, menopause, sleep schedule and metabolic health, so the range is a useful warning rather than a fixed conversion factor.
For treatment monitoring, aim for the same collection window each time, such as 7:00-9:00 a.m., after the same fasting period. A hypothetical change from 560 pg/mL at 8:00 a.m. to 300 pg/mL at 2:00 p.m. might reflect timing and food rather than a true 46% biological improvement.
Shift work and jet lag deserve special attention because sleep timing can alter the biological rhythm behind the clock time. Our asins analīžu laika plāna ceļvedis explains why a clock-based comparison can fail when the body schedule changes.
What is a normal CTX range?
There is no single normal CTX range that applies to every laboratory, assay, age group or sex. The most reliable reference interval is the one printed beside your result, interpreted with the assay name, fasting status, collection time and treatment history.

The table shows illustrative interpretation bands, not diagnostic ranges. CTX may be reported in pg/mL or ng/L, and those units are numerically equivalent; 500 pg/mL equals 500 ng/L, whereas 0.5 ng/mL equals 500 pg/mL.
Some European laboratories report manufacturer-specific premenopausal, postmenopausal and male intervals, while other laboratories use locally validated populations. Kantesti is an AI blood test interpretation platform that reads the laboratory's own reference interval before comparing a CTX result with general published patterns.
Age-related turnover is not a minor detail: growing adolescents can have much higher bone turnover than adults, and postmenopausal women often have higher CTX than premenopausal women. The medicīniskās validācijas informāciju describes why laboratory context and clinical review remain necessary for AI-assisted interpretation.
| Līmenis | Diapazons | Ko tas nozīmē |
|---|---|---|
| Illustrative untreated adult zone | 300-600 pg/mL | A possible mid-range result in some morning assays; not a universal normal interval. |
| Higher turnover signal | 600-900 pg/mL | May reflect increased resorption, but requires age, menopause, fasting and renal context. |
| Markedly high signal | 900-1,200 pg/mL | Consider untreated high turnover, recent fracture, endocrine disease or a sampling issue. |
| Ļoti augsts rezultāts | >1,200 pg/mL | Prompt clinical review is sensible; this is not an emergency threshold by itself. |
How do osteoporosis medicines lower CTX?
Antiresorptive medicines usually lower CTX because they reduce osteoclast activity. Oral or intravenous bisphosphonates, denosumab, hormone therapy and some selective estrogen receptor modulators can all produce lower CTX, but the speed and size of change differ substantially.

Bisphosphonates may reduce CTX over weeks to months, often by roughly 30-60% depending on the drug, adherence, baseline turnover and collection conditions. A low result during treatment generally indicates pharmacological suppression, not proof that bone has become structurally stronger at every skeletal site.
Denosumab acts more rapidly; clinical studies commonly observe CTX reductions of approximately 70-90% within days to weeks after injection, followed by recovery as the six-month dosing interval ends. A result taken near the end of an interval may therefore differ from one taken one month after treatment.
Medication lists should include dose, route, last administration date and missed doses. The osteoporosis blood test guide explains why calcium, phosphate, parathyroid hormone and kidney tests may clarify a CTX result better than CTX alone.
Which medicines can raise or complicate CTX?
Bone-building medicines can raise CTX temporarily, while some hormonal and endocrine medicines alter bone turnover indirectly. Teriparatide and abaloparatide commonly increase formation markers first and may also increase resorption; romosozumab often lowers CTX while increasing formation markers early in treatment.

A temporary CTX rise during teriparatide or abaloparatide does not automatically mean treatment is damaging bone. These medicines stimulate remodelling, so clinicians often interpret CTX with a formation marker such as P1NP and with the treatment's intended sequence.
Excess thyroid hormone, primary hyperparathyroidism and prolonged glucocorticoid exposure can disturb bone turnover, but their CTX patterns are not identical. Menopause can raise CTX as estrogen protection falls, while pregnancy and breastfeeding require separate physiological interpretation rather than adult treatment cutoffs.
Hormone status matters when reading results from women around menopause. Our women's health testing guide discusses why a CTX value should be linked to reproductive stage, symptoms and other laboratory findings.
Can kidney function make CTX look high?
Reduced kidney function can raise CTX because the kidneys help clear CTX fragments from the circulation. An elevated CTX in chronic kidney disease may therefore reflect both altered bone turnover and slower clearance, so it should not be interpreted with a healthy-kidney reference interval.

Creatinine and estimated glomerular filtration rate should be reviewed alongside CTX, especially when eGFR is below 60 mL/min/1,73 m². In advanced kidney disease, mineral and bone disorder can produce complex turnover states, and a serum CTX value may not reliably separate high turnover from impaired clearance.
A hypothetical patient with CTX of 840 pg/mL and eGFR of 38 mL/min/1.73 m² needs a different discussion from a patient with the same CTX and eGFR of 95. The first result may require kidney-mineral assessment, calcium, phosphate, parathyroid hormone and alkaline phosphatase before any osteoporosis conclusion.
Kidney-related interpretation also affects medication safety, particularly for some bisphosphonates. The high urine calcium guide shows how calcium handling tests can add context, although urine calcium does not replace CTX or DXA.
What else can cause a high CTX result?
High CTX can result from menopause, recent fracture healing, immobilisation, hyperparathyroidism, untreated hyperthyroidism, low calcium or vitamin D status, and some cancers affecting bone. The result becomes more informative when it matches the history and a related biochemical pattern.

Bone turnover often rises during fracture repair, so CTX drawn within weeks to months after a fracture may reflect healing biology. Immobilisation can also increase resorption; a person confined to bed for 4–8 nedēļām may not have a result comparable with their usual active baseline.
Vitamin D deficiency does not always produce a high CTX by itself, but low 25-hydroxyvitamin D combined with high parathyroid hormone and low-normal calcium can indicate secondary hyperparathyroidism. A 25-hydroxyvitamin D result below 20 ng/mL is commonly classified as deficient, although treatment thresholds vary by guideline and clinical setting.
Paget disease, hyperparathyroidism and other high-turnover disorders need targeted evaluation rather than a CTX-based label. Our Paget disease blood test explanation describes why alkaline phosphatase may be more useful for some focal bone processes.
When is CTX useful before osteoporosis treatment?
Before treatment, CTX can provide a baseline estimate of bone resorption and help identify a result that needs explanation before medication starts. It is most useful when collected fasting in the morning and interpreted with DXA, fracture history, kidney function and secondary-cause tests.

A baseline CTX above the laboratory's upper interval may support active turnover, but it does not decide treatment alone. A baseline below 100 pg/mL can occur in untreated people and does not guarantee low fracture risk because bone density, architecture and falls still matter.
The most useful baseline includes the date and time, hours fasting, exercise in the previous 24 hours, recent fracture, menstrual or menopause status, kidney function and medicines. Recording these variables can prevent a false impression that a later 25% change represents a treatment effect.
Kantesti can organise CTX with other uploaded laboratory values and trend dates, but treatment choice belongs to a qualified clinician. Our AI trend analyzer for medication safety is designed to help users see patterns that still need human medical review.
How should CTX be monitored during bisphosphonate treatment?
During bisphosphonate treatment, a falling CTX can support biological response, but the change must exceed expected analytical and biological variation. Monitoring is usually more meaningful after several months and when the same assay, fasting state and collection time are used.

A practical monitoring interval is often 3–6 mēnešu laikā, after starting or changing an oral bisphosphonate, although guidance and clinical circumstances differ. For example, a fall from 680 to 420 pg/mL may suggest response, but the clinician should verify adherence, timing, fasting status and laboratory method before calling it treatment failure.
The International Osteoporosis Foundation and International Federation of Clinical Chemistry position paper by Vasikaran et al. describes bone turnover markers as useful for monitoring treatment when standardisation and least-significant-change principles are respected. A result that changes by only 10% may be noise in a test with substantial within-person variation.
A persistently high CTX despite prescribed oral therapy may indicate missed doses, incorrect administration, malabsorption, very high baseline turnover or an assay problem. Review the osteoporosis treatment laboratory guide before assuming the medicine has failed.
What does CTX mean after denosumab?
After denosumab, CTX is expected to fall sharply and may rise again when the next dose is delayed or treatment stops. A rising result near the end of the six-month interval is not interpreted like a rising result several weeks after an injection.

Denosumab is commonly administered every 6 mēneši, and delayed treatment can allow bone resorption to rebound. A CTX result cannot determine independently whether an injection is safe to delay; clinicians use the dosing date, fracture history and an agreed transition plan.
After denosumab cessation, rebound bone turnover can be substantial and vertebral fracture risk may increase, especially when follow-on antiresorptive treatment is not provided. CTX may help monitor suppression during a transition, but no single universal post-denosumab target applies to every assay or patient.
Record the injection date to the nearest day, because a result at month 1 and a result at month 7 answer different clinical questions. A senior medication-effects review can also be useful; see medicine-related blood test patterns for broader interpretation principles.
Can CTX guide a bisphosphonate holiday?
CTX may contribute to decisions about a bisphosphonate treatment holiday, but it cannot by itself decide when treatment should stop or restart. Fracture risk, treatment duration, DXA trend, age, vertebral imaging and the specific bisphosphonate remain central.

Bisphosphonates remain in bone for years, so CTX may stay suppressed after treatment stops, particularly after intravenous zoledronic acid. A CTX of 150 pg/mL one year after stopping does not prove continued fracture protection, just as a CTX of 500 pg/mL does not automatically require immediate retreatment.
The evidence for using CTX thresholds to time a holiday is honestly mixed because studies use different assays, schedules and clinical outcomes. Eastell et al. describe this limitation in their review of bone turnover markers: biological plausibility is stronger than evidence for one universal decision cutoff.
The sākotnējo asins analīžu ceļvedis offers a useful preparation framework for repeat testing, including why a baseline should be comparable with follow-up rather than simply convenient.
How does CTX compare with DXA and fracture risk?
DXA measures areal bone mineral density, while CTX measures a changing biochemical signal of resorption; neither test fully captures bone strength alone. A person can have low CTX and low bone density, or high CTX with a DXA result that is not yet osteoporotic.

DXA results are expressed as T-scores or Z-scores, whereas CTX is usually reported in pg/mL, ng/L or ng/mL. A T-score of −2.5 is a diagnostic criterion in relevant adults; no CTX value has the same diagnostic status.
Fracture risk also depends on previous hip or vertebral fracture, glucocorticoid exposure, age, falls, family history, smoking, alcohol and secondary disease. The reason CTX combined with DXA is more useful than CTX alone is that turnover and accumulated density describe different parts of the risk pathway.
A fracture-risk calculator may incorporate clinical variables that CTX does not capture. Kantesti's AI biomarker interpretation can help place a CTX result beside the rest of a laboratory report, but it cannot see vertebral imaging or independently confirm a fracture history.
How should you prepare for a repeat CTX test?
For a useful repeat CTX test, reproduce the same fasting period, morning collection time, laboratory method and medication timing whenever possible. Consistency often improves interpretation more than chasing a particular number.
Ask whether the laboratory requests 8–12 stundas without calories and whether water is allowed. Avoid unusually strenuous exercise for the preceding day if your clinician advises it, and document illness, fracture, immobilisation, supplements and any missed osteoporosis dose.
Do not independently stop denosumab, bisphosphonates, thyroid replacement or glucocorticoids to alter CTX. Bring the exact drug name, dose, route and last dose date; a medication taken 2 days ago and an injection given 2 months ago have very different implications.
If the first sample was afternoon, non-fasting or processed by another assay, the clinician may prefer a new standardised baseline rather than a direct percentage comparison. Our blood test result timeline explains how timing, illness and medicines can create apparent changes.
How should you discuss CTX test results?
Discuss CTX with the clinician who knows your DXA, fracture history, kidney function and osteoporosis treatment plan. The most useful question is usually not “Is my CTX normal?” but “What does this result mean for my current clinical context and treatment timing?”
Bring the report's reference interval, units, collection time, fasting duration, recent meals, recent exercise and the date of your last osteoporosis medicine. A CTX of 400 pg/mL has a different meaning in an untreated 35-year-old, a postmenopausal person on alendronate and a patient with eGFR of 25.
Seek prompt medical advice for a new low-trauma hip or vertebral fracture, severe new back pain, marked height loss or symptoms suggesting calcium disturbance; CTX is not an emergency triage test. A very high value should usually lead to review, not panic, because sampling conditions and secondary causes can produce large differences.
Our AI blood test analysis tool can summarise CTX alongside related laboratory values and flag questions for follow-up, while its interpretation remains informational rather than a diagnosis or medication instruction. For technical details about how our AI works, see the Kantesti tehnoloģiju ceļvedis.
Bieži uzdotie jautājumi
Kāds CTX līmenis ir labs osteoporozes gadījumā?
There is no single CTX level that diagnoses or excludes osteoporosis. Some adult morning assays may show untreated results around 300-600 pg/mL, but age, menopause, kidney function, fasting, collection time and assay method can shift interpretation substantially. A DXA T-score of −2.5 or lower at a relevant skeletal site, or a qualifying fragility fracture, carries diagnostic importance that CTX does not. CTX is best used as a treatment-monitoring or bone-turnover marker alongside clinical assessment.
Should a CTX blood test be fasting?
Many laboratories request an overnight fast of 8-12 hours before a morning CTX blood test because food can suppress CTX for several hours. Water is usually allowed, but calories, milk and sweetened drinks can affect standardisation. Do not stop prescribed osteoporosis or thyroid medicines unless the ordering clinician tells you to do so. A fasting result collected at 8:00 a.m. is more comparable with another fasting result collected at a similar time than with an afternoon non-fasting sample.
What does a high CTX result mean?
A high CTX result suggests increased bone resorption or reduced clearance, but it does not prove osteoporosis. Menopause, recent fracture healing, immobilisation, hyperparathyroidism, untreated hyperthyroidism, low vitamin D with secondary parathyroid activity and kidney disease can all affect CTX. A result above 600 pg/mL may be high in some adult morning assays, while other laboratories use different intervals. The report should be reviewed with medication history, eGFR, calcium, phosphate, alkaline phosphatase, parathyroid hormone and DXA.
What does a low CTX result mean?
A low CTX result commonly indicates suppressed bone resorption, especially after bisphosphonate or denosumab treatment. Values below 100 pg/mL can occur during effective antiresorptive therapy, but they can also occur naturally or after a fasting morning collection. Low CTX does not prove that bone density is normal or that fracture risk is absent. Medication timing, treatment adherence, DXA findings and fracture history determine whether the result is reassuring or expected.
How quickly does denosumab lower CTX?
Denosumab can lower CTX rapidly, with reductions of approximately 70-90% reported within days to weeks in many treatment studies. CTX may rise again as the six-month dosing interval ends or when an injection is delayed. The result must therefore be interpreted against the exact injection date rather than a generic “on treatment” label. Denosumab should not be stopped or delayed without a clinician-directed plan because rebound bone turnover and vertebral fracture risk can occur after cessation.
Can kidney disease make CTX high?
Yes, reduced kidney function can raise CTX because the kidneys help clear CTX fragments and chronic kidney disease can alter mineral and bone metabolism. An eGFR below 60 mL/min/1.73 m² deserves particular caution, while advanced kidney disease can make standard osteoporosis reference intervals unsuitable. A CTX of 840 pg/mL with eGFR 38 is not interpreted like the same CTX with eGFR 95. Creatinine, eGFR, calcium, phosphate, parathyroid hormone and alkaline phosphatase should be reviewed together.
Uzziniet, kā lasīt asins analīžu rezultātus
Augšupielādējiet laboratorijas pārskatu, un Kantesti mākslīgais intelekts dažu sekunžu laikā vienkāršā valodā izskaidros katru biomarķieri. To izmanto vairāk nekā 2 miljoni cilvēku visā pasaulē.
Atsauces
- Klein, T., Mitchell, S., & Weber, H. (2026). Nipahas vīrusa asins analīze: agrīnas noteikšanas un diagnostikas ceļvedis 2026. Kantesti mākslīgā intelekta medicīniskie pētījumi. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). B negatīva asinsgrupa, LDH asins analīze un retikulocītu skaits: ceļvedis. Kantesti mākslīgā intelekta medicīniskie pētījumi. DOI
- Vasikaran S et al. (2011). Markers of bone turnover for the prediction of fracture risk and monitoring of treatment: a need for international reference standards. Osteoporosis International. DOI
- Eastell R et al. (2018). Bone turnover markers: are they clinically useful? European Journal of Endocrinology. DOI
- 2M+Analizētie testi
- 127+Valstis
- 100+Valodas
Par medicīnas komandu

Tomass Kleins, medicīnas doktors
Vadošais autors · Medicīniskais recenzents
Galvenais medicīnas darbinieks, Kantesti AI
Dr. Thomas Klein ir sertificēts klīniskais hematologs un internists ar vairāk nekā 15 gadu pieredzi laboratoriskajā medicīnā un ar mākslīgo intelektu atbalstītā klīniskajā analīzē.

Sāra Mičela, MD, PhD
Medicīnas konsultants
Galvenais medicīnas konsultants - klīniskā patoloģija un iekšējā medicīna
Dr. Sarah Mitchell ir sertificēta klīniskā patologe ar vairāk nekā 18 gadu pieredzi laboratorijas medicīnā un diagnostikas analīzē. Viņai ir specializētas sertifikācijas klīniskajā ķīmijā, un viņa plaši publicējusi pētījumus par biomarķieru paneļiem un laboratorijas analīzi klīniskajā praksē.

Profesors Dr. Hanss Vēbers, PhD
Piedalās eksperts
Laboratorijas medicīnas un klīniskās bioķīmijas profesors
Prof. Dr. Hans Weber ir ieguvis 30+ gadu pieredzi klīniskajā bioķīmijā, laboratorijas medicīnā un biomarķieru pētniecībā. Bijušais Vācijas Klīniskās ķīmijas biedrības prezidents, viņš specializējas diagnostikas paneļu analīzē, biomarķieru standartizācijā un ar AI atbalstītā laboratorijas medicīnā.
E-E-A-T uzticēšanās signāli
Pieredze
Ārstu vadīta klīniskā laboratorijas interpretācijas darbplūsmu pārskatīšana.
Ekspertīze
Laboratorijas medicīnas fokuss uz to, kā biomarķieri uzvedas klīniskā kontekstā.
Autoritāte
Medicīniski recenzējis Dr. Thomas Klein, piedaloties Dr. Sarah Mitchell un Prof. Dr. Hans Weber.
Uzticamība
Uz pierādījumiem balstīta interpretācija ar skaidriem turpmākās rīcības ceļiem, lai mazinātu trauksmi.
Turpināt lasīt
Vairāk medicīnisku ceļvežu no Kantesti medicīnas komandas:

Asins analīzes vairogdziedzera mezgla gadījumā: vissvarīgākie rezultāti
Uzziniet, ko TSH, vairogdziedzera antivielas un kalcitonīns atklāj par vairogdziedzera mezglu un kad nepieciešama ultrasonogrāfija vai audu izmeklēšana.
Lasīt rakstu →
Čūlainā kolīta asins analīze: uzliesmojuma pazīmes un ierobežojumi
Uzziniet, kuras asins analīzes palīdz diagnosticēt čūlaino kolītu un atklāt slimības uzliesmojumus vai komplikācijas, kā arī to, kāpēc endoskopija joprojām ir nepieciešama. Uzziniet, kā droši interpretēt rezultātus.
Lasīt rakstu →
CFU uz 1 ml urīna kultūras nozīme: urīnceļu infekcijas rādītāju interpretēšana
Uzziniet, ko urīna kultūrā nozīmē CFU/ml, kāpēc svarīgi ir simptomi un parauga savākšana un kā interpretēt zemu, augstu, jauktu,…
Lasīt rakstu →
Nejauši atklāts virsnieru veidojums: izmeklējumi, attēldiagnostika un turpmākā novērošana
Atklāts virsnieru incidentaloms? Uzziniet, kuri izmeklējumi, hormonu testi, novērošanas intervāli un steidzami brīdinājuma signāli ir svarīgi, un kādus jautājumus uzdot…
Lasīt rakstu →
Miegainība pēc ēšanas: cēloņi, glikozes pazīmes un turpmākie soļi
Pēc ēšanas nāk miegs? Uzziniet, kā maltītes lielums, diennakts ritms, miega trūkums, medikamenti un glikozes vielmaiņas traucējumi to veicina, kā arī par brīdinājuma pazīmēm…
Lasīt rakstu →
Zema urīnskābes līmeņa nozīme: cēloņi, simptomi un atkārtota pārbaude
Pazemināta urīnskābes līmeņa nozīme: uzziniet par biežākajiem medikamentu, uztura, nieru un ģenētiskajiem cēloņiem, simptomiem, noderīgiem izmeklējumiem un to, kad analīze jāatkārto…
Lasīt rakstu →Atklājiet visus mūsu veselības ceļvežus un ar AI darbinātus asins analīžu rezultātu analīzes rīkus vietnē kantesti.net
Medicīniskā atruna
Šis raksts ir paredzēts tikai izglītojošiem nolūkiem un nav medicīnisks padoms. Vienmēr konsultējieties ar kvalificētu veselības aprūpes speciālistu, lai pieņemtu lēmumus par diagnostiku un ārstēšanu.
Publicēts · Sazinieties ar redakcijas komandu
Publicējis Kantesti Ltd, reģistrēts Anglijā un Velsā, uzņēmuma reģistrācijas Nr. 17090423, Londona, Apvienotā Karaliste.